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Case Report

Combination targeted pulmonary hypertension therapy in the
resolution of Dasatinib-associated pulmonary arterial
hypertension
Arun Jose1, Hind Rafei2 and Jalil Ahari1
1
Pulmonary, Critical Care, and Sleep Medicine Division, The George Washington University, Washington DC, USA; 2Department of Medicine, The George
Washington University, Washington DC, USA

Abstract
Dasatinib is a small-molecule tyrosine kinase inhibitor used in the treatment of hematological malignancies. Pulmonary arterial
hypertension (PAH) is a rare but known complication. The mainstay of treatment is cessation of Dasatinib, and while clinical
improvement is rapid, complete hemodynamic resolution of pulmonary hypertension (PH) still remains exceedingly uncommon.
We present a case of Dasatinib-induced PAH in a woman with chronic myeloid leukemia, who demonstrated rapid and complete
clinical and hemodynamic resolution following treatment with combination pulmonary vasodilator therapy using an endothelin
receptor antagonist and a phosphodiesterase-5 inhibitor. This case suggests there may be an association between the use of
targeted PH medication in combination and the complete resolution of dasatinib-associated PAH, but further investigation is
required.
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Case description
A 61-year-old woman with no past history of cardiopulmonary disease was diagnosed with chronic myeloid leukemia
(CML) and initially started on Imatinib therapy. Four
years later, a bone marrow biopsy showed progression of
CML to precursor B-cell acute lymphoblastic leukemia
(ALL) and the patient was switched to therapy with
Dasatinib at a dose of 140 mg daily due to disease progression on Imatinib. At this time, the patient also received two
cycles of chemotherapy with Cyclophosphamide,
Vincristine, Adriamycin, and Dexamethasone. Following
this, a repeat bone marrow aspirate showed complete hematologic, cytogenetic, and molecular remission and the
patient was continued on Dasatinib therapy. However, 26
months later, the patient developed a persistent dry cough
and severe dyspnea on exertion. Initial laboratory testing
showed a white blood cell count of 3700, with 46% neutrophils and 45% lymphocytes. Blood cultures were negative

for infection, and the patient did not produce adequate
sputum for culture. A chest X-ray showed bilateral pleural
eﬀusions with cardiomegaly, suggestive of right ventricular
failure (Fig. 1). A CT scan was performed, which noted an
enlarged central pulmonary artery and bilateral pleural eﬀusions; no other abnormalities concerning the lung parenchyma, pulmonary veins, or interstitium were reported.
No pulmonary embolism was seen. An echocardiogram conﬁrmed the presence of a dilated and hypokinetic right ventricle and a dilated right atrium (Figs 2 and 3). Other
potential causes of pulmonary hypertension (PH) were
excluded by a negative V/Q scan and a review of past records showing normal echocardiographic testing one year
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Fig. 3. Echocardiography (apical four-chamber view) at time of initial
diagnosis of PAH.
Fig. 1. Chest X-ray at time of initial diagnosis of PAH.

Fig. 2. Echocardiography (apical two-chamber view) at time of initial
diagnosis of PAH.

Fig. 4. Chest X-ray after cessation of PAH-specific therapy.

prior. A right heart catheterization (RHC) was performed with a mean pulmonary artery pressure (mPAP) of
54 mmHg, pulmonary capillary wedge pressure (PCWP)
of 11 mmHg, and pulmonary vascular resistance (PVR) of
18.22 Woods Units, yielding a diagnosis of pulmonary arterial hypertension (PAH). The right atrial (RA) pressure was
19 mmHg, and the cardiac output (CO) by the Fick method
was 2.36 L/min (Cardiac index of 1.46 L/min/m2).
Vasoreactivity testing was not performed. In clinic followup one month after diagnosis, a D-dimer test was done and
found to be elevated at 1.73 mg/L (reference ¼ 0–0.5 mg/L);
however, a polymerase chain reaction (PCR) test for the
BCR-ABL gene was < 0.001% at that time, consistent
with her levels while in remission. A complete autoantibody
screen was also done and found to be negative (antinuclear
antibody, anti-double strand DNA, anti-Smith, ANCA,
ribonucleoprotein, anti-histone, SCL-70, chromatin, centromere, SSA/SSB). Her BNP was noted to be 560 pg/mL (reference ¼ 0–100 pg/mL), her 6-minute walk test (6MWT) was

250 m using 2 L oxygen via nasal cannula with a nadir pulse
oximetry saturation of 96%, and her functional class was
WHO-FC III. Dasatinib was suspected to be the precipitating factor for the patient’s new PAH given the temporal
association with the patient’s symptoms and exclusion of
other etiologies, and was promptly replaced with Nilotinib
(a related second-generation tyrosine kinase inhibitor with a
lower rate of drug-induced PAH compared with Dasatinib)
to continue therapy for CML. Given the severity of the
patient’s symptoms and RHC data, the patient was also
started on combination therapy with a phosphodiesterase5 inhibitor, Tadalaﬁl, at 20 mg daily and an endothelin
receptor antagonist, Ambrisentan, at 5 mg daily. The patient
was also started on furosemide at 10 mg daily and was not
started on systemic anticoagulation. The Tadalaﬁl was uptitrated over a period of four weeks to 40 mg daily, followed
by an up-titration of Ambrisentan to 10 mg daily over the
following four weeks. The patient experienced marked
symptomatic improvement, and repeat chest X-ray (Fig. 4)

Pulmonary Circulation

Fig. 5. Echocardiography (apical two-chamber view) after cessation of
PAH-specific therapy.

Fig. 6. Echocardiography (apical four-chamber view) after cessation of
PAH-specific therapy.

and echocardiogram four months after beginning therapy
showed complete resolution of the PH with a normal right
ventricular size and function (Figs 5 and 6). A repeat RHC
performed at the same time showed full resolution of PAH,
with mPAP of 18 mmHg, PCWP of 9 mmHg, and PVR of
1.96 Woods Units. The RA pressure was 5 mmHg and the
CO by the Fick method was 4.59 L/min (cardiac index of
2.51 L/min/m2). Her BNP was measured in clinic at this time
and had decreased to 18 pg/mL, her 6MWT had improved
to 425 m on room air with a nadir pulse oximetry saturation
of 96%, and her functional class was WHO-FC I. Given the
marked improvement both symptomatically and hemodynamically, Ambrisentan and furosemide were discontinued and Tadalaﬁl was weaned sequentially over the
following four months. Despite the cessation of her pulmonary vasodilator therapy, the patient did not have a return
of her dyspnea or exercise intolerance. She continues to
remain symptom-free after ﬁve months without targeted
PH therapy.

Discussion
Dasatinib is a potent oral small-molecule tyrosine kinase
inhibitor of the BCR-ABL oncogene used in the treatment
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of diseases such as CML and ALL.1,2 PAH has been
reported as a rare complication of Dasatinib therapy that
can occur at any time during the treatment course, ranging
from months to over one year after initiation.3
Drug-induced PH secondary to Dasatinib is rare, and the
exact mechanism is unknown but thought to be related to
the platelet-derived growth factor pathway (PDGF) and the
Src family of kinases.4 While its main therapeutic eﬀect in
CML patients is high-aﬃnity inhibition of the BCR-Abl
oncoprotein, Dasatinib is a non-speciﬁc tyrosine kinase
inhibitor and also inhibits a number of diﬀerent kinases,
including Src and the receptor for PDGF.2 In animal
models of PH, dysfunction of the PDGF pathway has
been involved in the development of PH, and the Src
family of kinases is involved in smooth muscle cell proliferation and vasoconstriction of the pulmonary vasculature.
More recent work has shown a direct link between
Dasatinib exposure and pulmonary endothelial cell
damage, dysfunction, and ultimately apoptosis in both a
rat PAH model and cultured human pulmonary endothelial
cells. Interestingly, treatment with Imatinib, a related tyrosine kinase inhibitor, did not have the same eﬀect.5 Indeed,
evidence suggests related inhibitors such as Nilotinib and
Imatinib do not have the same frequency of drug-induced
pulmonary vascular dysfunction as Dasatinib, and the pulmonary vascular toxicity for Dasatinib is molecule-speciﬁc.6
Some related tyrosine kinase inhibitors such as Imatinib
have also been used as treatment for PH, highlighting how
much is still unclear regarding the exact mechanism of druginduced PH from Dasatinib.7
While drug-induced PAH secondary to Dasatinib is
accompanied by serious clinical complications, evidence
suggests it may be reversible to some degree.8 To date, the
cornerstone of treatment is cessation of the oﬀending drug
in question; targeted PH medication is frequently used to
address the underlying hemodynamic and functional
abnormalities present. While this leads to rapid improvement in both symptoms of right heart failure and hemodynamic measures of PH severity, complete resolution of
PH is fairly uncommon. In an analysis of a French
Registry of nine Dasatinib-induced PAH cases, the initial
hemodynamic abnormalities seen on diagnostic RHC
(median mPAP of 46 mmHg, median PVR of 5.9 Woods
Units) improved signiﬁcantly with cessation of Dasatinib.
However, none of the patients had complete resolution of
PH at 15-month follow-up. This was despite two patients
receiving treatment with endothelin receptor antagonists
and one patient receiving therapy with calcium channel
blockers.9
Similarly, in an analysis of the Bristol-Meyers Squibb
database of adverse drug events due to Dasatinib, 41 cases
of PAH conﬁrmed by RHC due to Dasatinib were identiﬁed, of which there was symptomatic or echocardiographic
resolution of PAH in 21 cases. Only ﬁve patients had a
subsequent RHC following drug cessation, of which
none had complete resolution of PAH as deﬁned
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by mPAP < 25 mmHg at rest. While there was no relationship between the duration of Dasatinib exposure and
improvement of PAH (ranging from one week to 75
months of Dasatinib therapy), the majority of improved
cases (13 of 21, 62%) involved treatment with pulmonary
vasodilator medications such as endothelin receptor antagonists (ERA) or phosphodiesterase-5 inhibitors (PDE-5i).
Of note, two of the improved cases used combination targeted PH therapy with a PDE-5i and an ERA simultaneously, showing rapid clinical resolution in less than one
month. Unfortunately, following clinical resolution neither
case had a subsequent RHC to demonstrate hemodynamic
resolution of PAH.8
A PubMed/Medline search revealed several case reports
of Dasatinib-induced PAH, some of which resolved with
cessation of the drug alone,10,11 and others that resolved
with the addition of PAH-speciﬁc medications.12,13 These
reports diﬀer in both the duration of Dasatinib treatment
prior to the development of PAH, the type of PAH-speciﬁc
therapy used, as well as the duration of time required for
resolution of PAH; however, none of these published cases
involved the use of combination therapy. Notably only two
cases conﬁrmed complete hemodynamic resolution of PAH
with RHC, and both involved therapy with a PDE-5i
(Sildenaﬁl). The time to hemodynamic resolution was
seven months and six months, respectively.12,13 Currently
there are no data on the use of PAH-speciﬁc medication
to increase the extent and/or rapidity of Dasatinib-induced
PAH resolution, either alone or in combination.
As noted above, our patient was not anticoagulated, and
currently there is conﬂicting evidence regarding systemic
anticoagulation in PAH. The publication of the Registry
to Evaluate Early and Long-term PAH disease
Management (REVEAL) showed there was no survival
beneﬁt to systemic anticoagulation in idiopathic PAH
(IPAH) patients, and a trend towards increased mortality
in patients with systemic sclerosis-associated PAH (SScPAH). This is contrary to the Comparative, Prospective
Registry of Newly Initiated Therapies for Pulmonary
Hypertension (COMPERA) registry, which showed a statistically signiﬁcant survival beneﬁt at three years in IPAH
patients on systemic anticoagulation. Given the uncertainty
regarding the survival beneﬁt in IPAH patients, as well as
the concern for increased mortality in SSc-PAH exposed to
systemic anticoagulation, the decision is currently left to the
provider and patient on an individualized basis and the optimal strategy in drug-induced PAH patients is unknown.14,15
The use of combination targeted PH therapy in PAH
patients is supported by the AMBITION trial, where initial
combination therapy resulted in a 50% reduction in the rate
of clinical failure when compared with monotherapy in previously untreated patients with PAH.16 As noted above,
complete resolution of Dasatinib-induced PH is exceedingly
uncommon, but registries and case reports suggest there is
an association between the use of targeted PH medications
and complete resolution. We believe this case suggests a
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potential association between the use of combination targeted PH therapy and the complete resolution of
Dasatinib-associated PAH. It is unclear if combination therapy may be useful in increasing the chances of complete
resolution after drug cessation, and additional research is
warranted to investigate any potential association that
may exist.
Therapy with Dasatinib, a small-molecule tyrosine kinase
inhibitor used in the treatment of CML and ALL, is known
to cause drug-induced PAH. The mainstay of treatment is
cessation of Dasatinib, which can lead to improvement in
the severity of PAH but does not typically result in complete
resolution. As seen in this case, there may be an association
between the use of targeted PH medications in combination
and the complete resolution of PAH, but further investigation is required.
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